Sanofi Buys Freeslate’s Biologics Formulation System
The system automates sample preparation, sample stressing, and formulation analysis, allowing for the development of stable, robust formulations significantly faster with reduced API consumption.
Based on the Freeslate Core Module 3 (CM3) automation platform, the system combines liquid dispense and controlled heating/cooling/mixing with new automated measurements of pH, viscosity, and particle counting.
David Yamane, product marketing director at Freeslate, told BioPharma-Reporter that scientists can “assess biologics formulations faster and explore a broader biologics formulation and analytical space then they can today using manual methods.” He added that Sanofi does not have exclusive rights to the system.
“Unlike other vendors who treat biologics formulation development as a simple liquid handling application, Freeslate looked at the biologics formulation development workflow and designed a system that handles liquids and integrates both third party and Freeslate analytics to create a completely automated solution for formulation and analysis," Yamane said.
Amgen, Johnson & Johnson, KBI Biopharma and Novo Nordisk have implemented similar systems, he added.
"The analytics that Freeslate developed for this application include particle counting, color assessment, turbidity, viscosity, and high throughput pH measurement," he said.
Freeslate also employs Laboratory Executation and Analysis (LEA) software that “integrates the entire experimental process, from design through execution to data collection and analysis, and presentation of data. For data management, LEA software displays simultaneously the process and analytical data in one convenient view to accelerate knowledge-based decision making,” Yamane said.
